Conference Coverage
Conference Coverage
First visit for tuberous sclerosis complex comes months before diagnosis
HOUSTON – Many patients who eventually receive a diagnosis of tuberous sclerosis complex present with related complaints for months, or even years...
Conference Coverage
Machine learning beats clinical prediction of temporal lobe epilepsy surgery outcomes
HOUSTON – A machine learning interpretation of presurgical MRI studies did a better job of predicting which patients would have a successful...
Conference Coverage
Add-on fenfluramine reduces seizure frequency in Dravet syndrome
HOUSTON – Low-dose fenfluramine was found to reduce seizures significantly among a small cohort with Dravet syndrome without the appearance of...
Conference Coverage
Phase I results move Alzheimer’s candidate drug aducanumab into phase III trials
SAN DIEGO
Conference Coverage
Delays in Diagnosis and Treatment of Infantile Spasms Are Common
HOUSTON—Children with infantile spasms commonly endure substantial delays in diagnosis and treatment, according to research presented at the 70th...
Conference Coverage
Sigma-1 agonist presses forward after positive results in small Alzheimer’s trial
SAN DIEGO
Conference Coverage
MRI useful to distinguish between PACNS and neurosarcoidosis
WASHINGTON - MRI can help to differentiate between neurosarcoidosis and primary angiitis of the central nervous system, according to a single-...
Conference Coverage
Cardiovascular comorbidities common in patients with epilepsy
HOUSTON – Adults with epilepsy reported five of the six most common cardiovascular diseases more often than did adults without epilepsy, according...
Conference Coverage
TauRx still rooting for its methylene blue AD drug, despite controversial study results
SAN DIEGO – An anti-tau compound that has stirred scientific controversy for 8 years will continue along its developmental pathway at a much lower...
Conference Coverage
After full data release, experts say failed Alzheimer’s trial EXPEDITION 3 offers hopeful signals
SAN DIEGO – Solanezumab may have not have slowed the relentless march of Alzheimer’s disease, but it was a valuable proving ground of the amyloid...
Conference Coverage
IV brivaracetam similarly well tolerated as oral formulation
HOUSTON – Pooled data for a recently approved antiepileptic drug show good safety and tolerability when it’s administered intravenously.